Neuropeptides: ACTH-peptides in dementia

Area of Science:

• Neuroscience
• Pharmacology
• Geriatrics

Background:

• Adrenocorticotropic hormone (ACTH) neuropeptides are explored for treating cognitive decline.
• Focus on ACTH4-10 and the modified ACTH4-9 fragment, Org 2766, for oral administration.
• Relevance of animal and human studies for clinical effects in dementia.

Purpose of the Study:

• To review studies on ACTH neuropeptides for treating demented patients.
• To present results from a placebo-controlled dose-finding study of Org 2766 in Parkinson's disease with dementia (PDSD) patients.

Main Methods:

• Review of pharmacological and clinical data on ACTH4-10 and Org 2766.
• Placebo-controlled, dose-finding study involving 156 PDSD patients treated with Org 2766.
• Assessment of therapeutic effects using the SCAG total score and factor scores.

Main Results:

• Org 2766 demonstrated a significant therapeutic effect in PDSD patients, primarily on the SCAG total score.
• The observed improvement was modest (average 4 points on SCAG total), with clinically relevant effects in only 25% of patients.
• Analyses suggested effects on cognitive and somatic functions, but a clear dose-response relationship was not established.

Conclusions:

• Org 2766 shows potential therapeutic benefits for specific aspects of dementia in PDSD patients.
• Further confirmation by other researchers is necessary to establish the efficacy of Org 2766.
• The study highlights the need for replication to validate findings on Org 2766's efficacy in dementia treatment.